Sunday, August 11, 2019 10:11:37 PM
Raising hell by patient advocates, friendly oncologists and the general public after a CRL or no-approval decision by the FDA is too late.
NWBO's strategy of silence for fear of upsetting the FDA and possibly compromising a chance for approval all the while allowing the free fall of the share price is completely misplaced. Malevolents like AF have had a field day running rings around two lawyers who should know, and assumedly can do, better. Blaming the share price cratering on naked shorts has worn thin especially after statements from LG that a string of PRs would also include announcing action against such malevolents. Rings hollow and sounds very much like "the dog ate my home work for lunch." When nothing happened and asked WTF is CB doing, LG sheepishly averred that it is not the "right time." NWBO management has not met a timeline they did not miss---and by miles.
I have been a regulatory lawyer and worked with regulatory agencies in the US. These agencies have their own agendas. They will not be "nice" to those whom they regulate, even if they are "nice" and keep silent. It is a sign of weakness especially from a small company. The agency strongly believes it has leverage and the meek regulated party will do nothing and roll-over. I have seen this time and again. Agencies don't want trouble especially from a squeaky wheel. NWBO is a relatively unknown factor because it has been so quiet. It is hardly mentioned in the literature and when it rarely is, the information is either dated or even wrong. The FDA may believe that even if it releases a CRL pending ultimate approval that there will be relatively little or no push back. "Who the hell is NWBO"?
The time to break silence is now and not after a decision by the FDA. IMHO, the strategy of silence has proven to be deadly, not golden.
Recent NWBO News
- Biophma Announces Exclusive In License for Dendritic Cell Technology, Sending Shares Higher • AllPennyStocks.com • 06/17/2024 04:40:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/04/2024 09:11:16 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 06/03/2024 09:22:55 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 05/22/2024 08:13:36 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/10/2024 09:04:57 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 03/01/2024 10:04:38 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/02/2023 01:31:35 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/16/2023 10:11:54 PM
- Epazz, Inc. (OTC Pink: EPAZ) ZenaDrone Demonstration to Defense Departments of UAE and Saudi Arabia • InvestorsHub NewsWire • 11/15/2023 12:19:31 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/09/2023 09:30:39 PM
- Epazz, Inc. (OTC Pink: EPAZ) US Navy Collaboration ZenaDrone 1000 • InvestorsHub NewsWire • 11/09/2023 01:00:34 PM
- Epazz, Inc. (OTC Pink: EPAZ) US Navy Collaboration ZenaDrone 1000 Extreme Weather Demo • InvestorsHub NewsWire • 11/07/2023 12:29:43 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/09/2023 08:36:14 PM
Last Shot Hydration Drink Announced as Official Sponsor of Red River Athletic Conference • EQLB • Jun 20, 2024 2:38 PM
ATWEC Announces Major Acquisition and Lays Out Strategic Growth Plans • ATWT • Jun 20, 2024 7:09 AM
North Bay Resources Announces Composite Assays of 0.53 and 0.44 Troy Ounces per Ton Gold in Trenches B + C at Fran Gold, British Columbia • NBRI • Jun 18, 2024 9:18 AM
VAYK Assembling New Management Team for $64 Billion Domestic Market • VAYK • Jun 18, 2024 9:00 AM
Fifty 1 Labs, Inc Announces Acquisition of Drago Knives, LLC • CAFI • Jun 18, 2024 8:45 AM
Hydromer Announces Attainment of ISO 13485 Certification • HYDI • Jun 17, 2024 9:22 AM